NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

UK Ibrance Patient Program (IPP) Study

CompletedN/A

Sponsor: Pfizer

Conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer

Interventions: Palbociclib

Countries: United Kingdom

What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer treated as part of the IPP?

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

All patients meeting the following eligibility criteria will be included in the study:

* Patients enrolled into the IPP at one of the selected hospitals (see Annex 1 for IPP enrolment letter).
* Patients who received ≥1 dose of palbociclib as part of the IPP at one of the selected sites.
* For sites where data collection is performed by pH Associates, written informed consent will be required from living patients to access their medical records.
* Patient aged ≥18 years old at enrollment into the IPP

Locations (8)

Truro, Cornwall, United Kingdom
Brighton, United Kingdom
Glasgow, United Kingdom
London, United Kingdom
Maidstone, United Kingdom
Manchester, United Kingdom
Metropolitan Borough of Wirral, United Kingdom
Newcastle upon Tyne, United Kingdom